Shapes the strategy for pre-clinical drug development and executes it.Contributes to the day-to-day company operations.

Led multiple collaborative projects with other Buck and external research groups that resulted in 2 first-author publications. These projects entailed the development of a high-throughput method to measure senescence burden and the identification of sub-populations of senescent cells with different sensitivity to senolytic treatment.Supported the organization and coordination of multiple international aging conferences, including managing all volunteer operations for the… Show more Led multiple collaborative projects with other Buck and external research groups that resulted in 2 first-author publications. These projects entailed the development of a high-throughput method to measure senescence burden and the identification of sub-populations of senescent cells with different sensitivity to senolytic treatment.Supported the organization and coordination of multiple international aging conferences, including managing all volunteer operations for the Seno-Therapeutic Summit 2023 and assisting with the Longevity Summit 2022 and 2023. Show less

Created a step-by-step workflow to generate and analyze senescent-associated secretory phenotype (SASP) samples, leading to a first-author publication. This involved collecting several protocols developed by colleagues and carefully distilling them into a generalized and clear workflow.Aided multiple projects led by other lab members, which resulted in 2 publications in peer-reviewed journals. My role involved preparing senescent samples using primary human cell… Show more Created a step-by-step workflow to generate and analyze senescent-associated secretory phenotype (SASP) samples, leading to a first-author publication. This involved collecting several protocols developed by colleagues and carefully distilling them into a generalized and clear workflow.Aided multiple projects led by other lab members, which resulted in 2 publications in peer-reviewed journals. My role involved preparing senescent samples using primary human cell strains.Performed lab managing duties, including setting up centralized laboratory resources to share tested protocols and reagents among lab members, general maintenance of lab equipment, and purchasing new instruments. Show less

Contributed to characterizing the heterogeneity of the senescent-associated secretory phenotype (SASP) from cell culture senescence models, which resulted in a published manuscript in a peer-reviewed journal. Specifically, I prepared SASP samples, which involved culturing primary human cell strains, inducing cellular senescence in such cell culture models, and validating senescence induction via multiple molecular biology assays (e.g. immunocytochemistry, RT-qPCR, western blotting).

Established MYCN potential role in the upregulation of plasma membrane transporters SLC7A1 and SLC7A2 as measured by a luciferase assay in a MYCN-inducible neuroblastoma cell line. This involved the cloning of SLC7A1 and SLC7A2 promoter regions into a luciferase reporter plasmid, their transfection into the neuroblastoma cell line, and carrying out luciferase assays.